Diogo de Sousa Neves, Shalini Jayasekar Zürn, Thuy Khuc-Bilon, Melissa Rendler-Garcia, Yehoda M Martei, Sumithra Krishnamurthy Reddiar
{"title":"肿瘤药物获取联盟:加强国内协调,促进可持续获取。","authors":"Diogo de Sousa Neves, Shalini Jayasekar Zürn, Thuy Khuc-Bilon, Melissa Rendler-Garcia, Yehoda M Martei, Sumithra Krishnamurthy Reddiar","doi":"10.2147/CMAR.S459873","DOIUrl":null,"url":null,"abstract":"<p><p>The disparity in access to essential cancer medicines between less and more affluent countries is a major source of inequities in access to cancer care. In May 2022, the Union for International Cancer Control (UICC) launched a new initiative, the Access to Oncology Medicines Coalition (ATOM Coalition), bringing together over 40 organisations from the private and civil society sectors to cooperate and combine resources to address key barriers of access to cancer medicines in low- and lower-middle income countries. While the ATOM Coalition is engaged in global efforts to make cancer medicines more accessible, the initiative also includes a country-level support programme to enhance coordinated locally-led action and accelerate access. This is supported by a transparent governance and organisational structure as well as a working framework with governments and other key stakeholders to assess the current capacity and develop tailored responses that can lift and/or relax some of the identified barriers through joint collaborations with ATOM Coalition partners.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"16 ","pages":"1609-1616"},"PeriodicalIF":2.5000,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11579523/pdf/","citationCount":"0","resultStr":"{\"title\":\"The Access to Oncology Medicines Coalition: Enhanced in-Country Coordination for Sustainable Access.\",\"authors\":\"Diogo de Sousa Neves, Shalini Jayasekar Zürn, Thuy Khuc-Bilon, Melissa Rendler-Garcia, Yehoda M Martei, Sumithra Krishnamurthy Reddiar\",\"doi\":\"10.2147/CMAR.S459873\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The disparity in access to essential cancer medicines between less and more affluent countries is a major source of inequities in access to cancer care. In May 2022, the Union for International Cancer Control (UICC) launched a new initiative, the Access to Oncology Medicines Coalition (ATOM Coalition), bringing together over 40 organisations from the private and civil society sectors to cooperate and combine resources to address key barriers of access to cancer medicines in low- and lower-middle income countries. While the ATOM Coalition is engaged in global efforts to make cancer medicines more accessible, the initiative also includes a country-level support programme to enhance coordinated locally-led action and accelerate access. This is supported by a transparent governance and organisational structure as well as a working framework with governments and other key stakeholders to assess the current capacity and develop tailored responses that can lift and/or relax some of the identified barriers through joint collaborations with ATOM Coalition partners.</p>\",\"PeriodicalId\":9479,\"journal\":{\"name\":\"Cancer Management and Research\",\"volume\":\"16 \",\"pages\":\"1609-1616\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2024-11-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11579523/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Management and Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/CMAR.S459873\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Management and Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/CMAR.S459873","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
较不富裕国家和较富裕国家在获得基本抗癌药物方面的差距是造成癌症治疗不公平的主要原因。2022 年 5 月,国际癌症控制联盟(UICC)发起了一项新倡议--"获取肿瘤药物联盟"(ATOM Coalition,简称 ATOM 联盟),汇集了来自私营和民间社会部门的 40 多个组织,通过合作和资源整合,解决低收入和中低收入国家在获取抗癌药物方面的主要障碍。ATOM 联盟在全球范围内努力提高癌症药物的可及性,同时该倡议还包括一项国家级支持计划,以加强当地主导的协调行动,加快药物的可及性。该计划由一个透明的管理和组织结构以及一个与政府和其他主要利益相关方合作的工作框架提供支持,以评估当前的能力并制定有针对性的应对措施,通过与 ATOM 联盟合作伙伴的联合协作,消除和/或放宽一些已确定的障碍。
The Access to Oncology Medicines Coalition: Enhanced in-Country Coordination for Sustainable Access.
The disparity in access to essential cancer medicines between less and more affluent countries is a major source of inequities in access to cancer care. In May 2022, the Union for International Cancer Control (UICC) launched a new initiative, the Access to Oncology Medicines Coalition (ATOM Coalition), bringing together over 40 organisations from the private and civil society sectors to cooperate and combine resources to address key barriers of access to cancer medicines in low- and lower-middle income countries. While the ATOM Coalition is engaged in global efforts to make cancer medicines more accessible, the initiative also includes a country-level support programme to enhance coordinated locally-led action and accelerate access. This is supported by a transparent governance and organisational structure as well as a working framework with governments and other key stakeholders to assess the current capacity and develop tailored responses that can lift and/or relax some of the identified barriers through joint collaborations with ATOM Coalition partners.
期刊介绍:
Cancer Management and Research is an international, peer reviewed, open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival, and quality of life for cancer patients. Specific topics covered in the journal include:
◦Epidemiology, detection and screening
◦Cellular research and biomarkers
◦Identification of biotargets and agents with novel mechanisms of action
◦Optimal clinical use of existing anticancer agents, including combination therapies
◦Radiation and surgery
◦Palliative care
◦Patient adherence, quality of life, satisfaction
The journal welcomes submitted papers covering original research, basic science, clinical & epidemiological studies, reviews & evaluations, guidelines, expert opinion and commentary, and case series that shed novel insights on a disease or disease subtype.